PureTech's Wholly Owned Programs are designed to enhance on-target efficacy, enable oral administration or improve tolerability to unlock new classes of medicine that have been held back by one of these issues.
PureTech's Wholly Owned Programs are designed to enhance on-target efficacy, enable oral administration or improve tolerability to unlock new classes of medicine that have been held back by one of these issues.
Our programs1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Idiopathic pulmonary fibrosis (IPF)

2b

IPF

~120K in US

~110K in EU5


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for radiation induced fibrosis; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (IPF-ILDs) and exploring LYT-100 in myocardial and other organ system fibrosis.

LYT-200
Anti-Galectin-9 MAb
Solid tumors and hematological malignancies

1/2

Solid tumors

~82K/year U.S. (Bladder cancer)
~66K/year U.S. (Head and neck cancers)
~20K/year U.S. (AML)


Fully human IgG4 monoclonal antibody, or mAb, designed to inhibit the activity of galectin-9, an immunomodulatory molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells. We are developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. We are also developing LYT-200 for the treatment of hematological malignancies, such as acute myeloid leukemia (AML).

LYT-300
Oral Allopregnanolone
Depression, anxiety & related indications

1

Depression, anxiety & related indications

Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety and depression. Allopregnanolone is a positive allosteric modulator of GABAA receptors that has therapeutic potential across a wide range of neurological conditions, including depression and anxiety disorders, though its therapeutic application has been limited due to high first pass metabolism. Our Glyph platform reversibly links a drug to a dietary fat molecule, creating a novel prodrug. We believe this technology has the potential to provide a broadly applicable means of enhancing the bioavailability of certain orally administered drugs that would otherwise be limited by first-pass liver metabolism.

LYT-310
Oral Cannabidiol
Epilepsies & other neurological indications

Preclinical

Epilepsies & other neurological indications

Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.

Phase completed
Phase in progress
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.

Developing breakthrough medicines at PureTech